Clinical trial · Observational
Use of Fluorescein Dye for the Removal of Brain Tumors
NCT02389530CI-TRIAL-00034127completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Fluorescein is a dye agent that can be injected through an intravenous line. It has been shown to help tell the difference between brain tumor tissue and normal brain tissue when it is used together with a specialized filter on a microscope in the operating room. The investigators plan to study the use of fluorescein in the removal of brain tumors at a low dose.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Neoplasms | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fluorescein | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- interventional group
- description
- All participants will receive the study intervention, intravenous administration of fluorescein dye prior to brain tumor removal.
- interventionNames
- Drug: Fluorescein
Primary outcomes (1)
- measure
- Adverse event assessment
- timeFrame
- 3 years
- description
- Assessment of frequency of adverse events related to fluorescein administration, especially anaphylaxis
Secondary outcomes (2)
- measure
- Degree of tumoral resection
- timeFrame
- 3 years
- description
- Volumetric assessment of amount of tumor removed, compared to historical controls
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age of 18 or greater 2. Plan for elective removal of a brain tumor at UPMC Shadyside with either Dr. Engh or Dr. Amankulor. Exclusion Criteria: 1. History of adverse reaction to fluorescein. 2. Emergent surgical procedure (consent not feasible). 3. Creatinine of \> 2.0 (drug is excreted renally). 4. Known ongoing pregnancy.
References
Publications (0)
Data not yet available
No reference posted for this study.